Venture&Growth Archives - Gilde Healthcare

latest news
Venture&Growth

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Implantable shock absorber demonstrates clinically meaningful pain relief and functional improvement in data presented at OSET
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

test Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Amphista is a world leading next-generation Targeted Protein Degradation (TPD) company with the […]

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

test Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s successful Ev-AIFib Study. The Proof-of-Concept-Study investigated the use of Volta’s lead product VX1, an expertise-based AI software solution to assist […]

Gilde Healthcare company Nalu appoints Thomas West as new president and CEO

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision...

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a nitinol expander designed to...

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds a new era in digital medicine. The NICE guidance states that Sleepio, Big...

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to...

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion...

Gilde Healthcare company ADCendo appoints Dominik Mumberg, PHD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immuno-oncology and small molecules Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Adcendo ApS (“Adcendo”), a therapeutics company focused on the development of breakthrough antibody-drug conjugates...
Loading...
These were all messages
02f3cc09bb